News coverage about Covance (NYSE:CVD) has trended somewhat positive recently, according to Accern. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Covance earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave media stories about the healthcare company an impact score of 44.5825130242613 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
CVD stock remained flat at $$107.07 during midday trading on Monday.
COPYRIGHT VIOLATION WARNING: “Covance (CVD) Getting Somewhat Favorable News Coverage, Study Shows” was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://baseballnewssource.com/2018/04/02/covance-cvd-getting-somewhat-positive-press-coverage-accern-reports/2004466.html.
Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.
Receive News & Ratings for Covance Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance and related companies with MarketBeat.com's FREE daily email newsletter.